EPO grants Brookhaven patent for use of vigabatrin in prevention of addiction to opioids

More info…
Catalyst Pharmaceutical Partners, Inc. today announced that the European Patent Office (EPO) granted to Brookhaven Science Associates/Brookhaven National Laboratory (Brookhaven) a European patent for the use of vigabatrin for the prevention of addiction to opioids (e.g., oxycodone, hydrocodone) used in pain management.

drug abuse statistics

The Call Is Free

Call Now 1-877-995-8374
Posted in Drug Abuse Helpline  |  Leave a comment

Leave a reply